INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEO

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving NeoGenomics and its officers or directors, following disappointing financial results and a significant stock price drop [1][3][4]. Financial Performance - NeoGenomics reported second-quarter 2025 revenue of $181.3 million, which was below consensus estimates, and a net loss of $45.1 million [3]. - The company revised its 2025 revenue forecast down to a range of $720 million to $726 million, a decrease from the previous estimate of approximately $753 million [3]. - Adjusted EBITDA projections were also lowered to a range of $41 million to $44 million, down from a prior range of $55 million to $58 million [3]. Stock Market Reaction - Following the release of the financial results, NeoGenomics' stock price fell by $1.21 per share, or 18.73%, closing at $5.25 per share on July 29, 2025 [4].